Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Astellas signs deal with AAV gene therapy firm Dyno

by Michael McCoy
December 4, 2021 | A version of this story appeared in Volume 99, Issue 44

 

Astellas Pharma will pay $18 million to Dyno Therapeutics as part of a pact to develop gene therapies delivered with adeno-­associated virus (AAV) capsids made using Dyno’s CapsidMap technology. Dyno says the technology is suited to optimize AAV capsids for delivery to multiple organs. The agreement with Astellas will focus on skeletal and cardiac muscle diseases. Astellas says it became a leader in genetic medicines after it acquired Audentes Therapeutics last year for $3 billion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.